Previous 10 | Next 10 |
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its chief financial officer, Frank Stokes, was named to Finance & Investing’s Top 25 CFOs of Houston list for 2023. This year’s awardees are...
Additional presentation on Castle’s pipeline test for inflammatory skin diseases highlights unmet clinical need Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data on DecisionDx ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of data from a prospective, multicenter study, called DECIDE. 1,2 In the study, DecisionDx®-Melanoma test results influenced 85% of clinic...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2022, after the close of market on Tuesday, Feb. 28, 2023. Company ma...
Award recognizes Castle’s people-first culture built on the Company’s values of excitement, collaboration, integrity, innovation, trust and excellence Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, toda...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s medical director, Matthew Goldberg, M.D., F.A.A.D., board-certified dermatologist and dermatopathologist, will present at the Precision M...
Real-world data from Castle’s collaboration with the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) program registries confirm ability of DecisionDx®-Melanoma to identify patients with high-risk tumor biology in a cohort of patients with a negativ...
Castle Biosciences ( NASDAQ: CSTL ) said it expects to meet or exceed the top end of its previously guided range of $132M-$137M million for full-year 2022 total revenue vs. consensus at $135.6M. The company delivered 12,563 total test reports in the fourth quarter of 2022, compare...
2022 total revenue expected to meet or exceed top end of guided range of $132 – 137 million Delivered 44,338 total test reports in 2022, an increase of 58% compared to 2021 Growth of 37% year over year in DecisionDx ® -Melanoma test report volume Year-e...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Accreditation Committee of the College of American Pathologists (CAP) has accredited its clinical laboratory facility in Pittsburgh. This achiev...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...